Pathology of recombinant human transforming growth factor-beta 1 in rats and rabbits.
The systemic administration of high doses of rHuTGF-beta 1 to rats produced a spectrum of lesions in multiple target tissues, including liver, bone, kidney, heart, thymus, pancreas, stomach, cecum, at the injection vein, and in skeletal muscle at the site of anesthetic injection. The majority of these lesions can be attributed to known biological activities of TGF-beta 1. High-dose dermal application resulted in local effects at the wound sites without systemic toxicity.
Terrell
T G
TG
Department of Safety Evaluation, Genentech, Inc., South San Francisco, California 94080.
Working
P K
PK
Chow
C P
CP
Green
J D
JD
D000818:Animals; D016466:CHO Cells; D002460:Cell Line; D006224:Cricetinae; D005260:Female; D006801:Humans; D007271:Injections, Intradermal; D007275:Injections, Intravenous; D008297:Male; D009929:Organ Size / Q000187:drug effects; D011817:Rabbits; D051381:Rats; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000633:toxicity; D012867:Skin / Q000187:drug effects; D016212:Transforming Growth Factor beta / Q000008:administration & dosage / Q000633:toxicity*; D014781:Viscera / Q000187:drug effects / Q000473:pathology; D015431:Weight Loss / Q000187:drug effects; D014945:Wound Healing / Q000187:drug effects
D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta